649 Phase 1/2 study of AgenT-797, an allogeneic invariant natural killer T (iNKT) cell therapy, in subjects with moderate to severe acute respiratory distress syndrome (ARDS) secondary to SARS-CoV-2 (COVID-19)

Marco Purbhoo,Darrian Moskowitz,Mark Exley,Maurice Kirby,Terese Hammond,Don Stevens,Burcu Yigit,Koen Van Besien,Alexa Buffa,Xavier Michelet,Rachel Smith,Waldo Ortuzar Feliu,Sonia De Munari

doi:10.1136/jitc-2022-sitc2022.0649

649 Phase 1/2 study of AgenT-797, an allogeneic invariant natural killer T (iNKT) cell therapy, in subjects with moderate to severe acute respiratory distress syndrome (ARDS) secondary to SARS-CoV-2 (COVID-19)

Marco Purbhoo, Darrian Moskowitz + Show 11 more

Open Access

PDF Available

https://doi.org/10.1136/jitc-2022-sitc2022.0649

Copy DOI

Export

Save

Cite

Journal: Journal for ImmunoTherapy of Cancer	Publication Date: Nov 1, 2022
Citations: 1

Affiliation: Saint John's Health Center, Providence College, Norton Healthcare, Cornell University, Agenus (United States)

#Severe Acute Respiratory Distress Syndrome #Viral Acute Respiratory Distress Syndrome #iNKT Cell #Acute Respiratory Distress Syndrome #Acute Respiratory Distress Syndrome Symptoms #Prevention Of Secondary Infections #Rapid Extubation #Berlin Definition #Mechanically Ventilated #Cytokine Release Syndrome

Abstract
Full-Text PDF
Similar Papers

Abstract

Listen

BackgroundAgenT-797 is a novel allogeneic iNKT cell therapy demonstrating activity in malignances and serious viral infections (i.e., SARS-CoV-2). In response to inflammatory injury, iNKTs home to critical organs, including lungs,...

Full Text

Published Version (Free)

View/Download pdf

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal for ImmunoTherapy of Cancer

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

649 Phase 1/2 study of AgenT-797, an allogeneic invariant natural killer T (iNKT) cell therapy, in subjects with moderate to severe acute respiratory distress syndrome (ARDS) secondary to SARS-CoV-2 (COVID-19)